Abstract
Solid tumors require angiogenesis for their growth and to form metastatsis. Many new cancer therapies are directed against tumor vessels. Radiation therapy is one of the most widely used treatments for a wide variety of tumors, and is thought to act by directly targeting clongenes, as well as was induce apoptosis of endothelial cells, and reduce angiogenesis. Vascular targeting agents are aimed specifically at the existing tumor vasculature. Anti-angiogenic agents target angiogenesis or new growth of tumor vessels. Recent preclinical studies have suggested that radiotherapy in combination with antiangiogenic agents enhances the therapeutic ratio of ioninzing radiation alone. Targeting tumor vasculature has strong biological rationale in radiation therapy and preclinical studies consistently show an increase in radiationsensitization with combined treatment. This review article explores the complex interaction between radiation therapy and antiangiogenic agents. Furthermore we discuss the efficacy of combined radiotherapy and AT1-R antagonist (TCV-116) on tumor associated angiogenesis.
Keywords: Angiogenesis, radiationtherapy, anti-angiogenic agents, combination therapy, angiotensin type 1 receptor
Current Signal Transduction Therapy
Title: Combined Effect of Anti-Angiogentic Agents, Angiotensin Type 1 Receptor Antagonists and Radiation Therapy
Volume: 5 Issue: 3
Author(s): Hideki Amano, Yuichiro Ohnuma, Yuzuru Niibe, Kazushige Hayakawa, Yukitoshi Satoh and Masataka Majima
Affiliation:
Keywords: Angiogenesis, radiationtherapy, anti-angiogenic agents, combination therapy, angiotensin type 1 receptor
Abstract: Solid tumors require angiogenesis for their growth and to form metastatsis. Many new cancer therapies are directed against tumor vessels. Radiation therapy is one of the most widely used treatments for a wide variety of tumors, and is thought to act by directly targeting clongenes, as well as was induce apoptosis of endothelial cells, and reduce angiogenesis. Vascular targeting agents are aimed specifically at the existing tumor vasculature. Anti-angiogenic agents target angiogenesis or new growth of tumor vessels. Recent preclinical studies have suggested that radiotherapy in combination with antiangiogenic agents enhances the therapeutic ratio of ioninzing radiation alone. Targeting tumor vasculature has strong biological rationale in radiation therapy and preclinical studies consistently show an increase in radiationsensitization with combined treatment. This review article explores the complex interaction between radiation therapy and antiangiogenic agents. Furthermore we discuss the efficacy of combined radiotherapy and AT1-R antagonist (TCV-116) on tumor associated angiogenesis.
Export Options
About this article
Cite this article as:
Amano Hideki, Ohnuma Yuichiro, Niibe Yuzuru, Hayakawa Kazushige, Satoh Yukitoshi and Majima Masataka, Combined Effect of Anti-Angiogentic Agents, Angiotensin Type 1 Receptor Antagonists and Radiation Therapy, Current Signal Transduction Therapy 2010; 5 (3) . https://dx.doi.org/10.2174/157436210791920292
DOI https://dx.doi.org/10.2174/157436210791920292 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Medication-Induced Nephrotoxicity in Older Patients
Current Drug Metabolism Nonalcoholic Fatty Liver Disease and Cardiovascular Disease
Current Pharmaceutical Design Medical Therapy for Long QT Syndrome
Mini-Reviews in Medicinal Chemistry Potential Contribution of Action of Renin Angiotensin System to Bone Metabolism
Current Hypertension Reviews Association Between Polycystic Ovary Syndrome and Metabolic Syndrome
Current Medicinal Chemistry Aspartic Proteases in Drug Discovery
Current Pharmaceutical Design Review of Olmesartan Medoxomil in Achieving Guideline-Recommended Target BP Goals and Implications for Managed Care
Current Hypertension Reviews Advances in Angiotensin Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs)
Mini-Reviews in Medicinal Chemistry Anti-inflammatory Action of Green Tea
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Prediction of Bioactive Compound Pathways Using Chemical Interaction and Structural Information
Combinatorial Chemistry & High Throughput Screening Safety and Efficacy of Duloxetine in the Treatment of Diabetic Peripheral Neuropathic Pain in Older Patients
Current Drug Safety Editorial (Novel Therapies and Botanical and Mechanical Approaches for Management of Cardiovascular Disease)
Recent Patents on Cardiovascular Drug Discovery Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Current Pharmaceutical Design Momordica balsamina: A Medicinal and Neutraceutical Plant for Health Care Management
Current Pharmaceutical Biotechnology Immunotherapy in a Rabbit Model of Alzheimer’s Disease
Drug Delivery Letters Recent Progress of Medicinal Chemistry Research on Peroxisome Proliferator-Activated Receptor (PPAR) Ligands for the Treatment of Metabolic Syndrome
Current Bioactive Compounds Editorial [Hot Topic: Complications in Pregnancy - Recent Developments in Preventive Strategies and Treatment Modalities (Executive Editor: A.C. Bolte)]
Current Pharmaceutical Design Nano-constructed Carriers Loaded With Antioxidant: Boon For Cardiovascular System
Current Pharmaceutical Design Persistent Pulmonary Hypertension of the Newborn: Physiology, Hemodynamic Assessment and Novel Therapies
Current Pediatric Reviews Context-Dependency of Relations Between Cardiovascular Phenotypes and Genes Involved in Sodium Homeostasis: Findings from the European Project on Genes in Hypertension
Current Hypertension Reviews